Therapy to Obese Type 2 Diabetes Mellitus:How Far Will We Go Down the Wrong Road?

被引:0
|
作者
HENG Xianpei [1 ]
LI Xiujun [2 ]
LI Liang [1 ]
YANG Liuqing [1 ]
WANG Zita [1 ]
HUANG Suping [3 ]
机构
[1] 不详
[2] Department of Endocrinology, People's Hospital Affiliated to Fujian University of Traditional Chinese Medicine
[3] 不详
[4] West China Medical Center of Sichuan Medical University West China University of Medical Science
[5] Academy of Integrative Medicine Fujian, Fujian University of Traditional Chinese Medicine
[6] 不详
关键词
D O I
暂无
中图分类号
R587.1 [糖尿病];
学科分类号
摘要
Traditional glucose-lowering chemical agents, including various types of insulin and insulin secretagogues, insulin sensitizers, gliptins, etc., are based on diabetic pathogenesis of insulin resistance(IR) and islet insufficiency. Numerous evidence-based medical studies have shown that these traditional hypoglycemic chemical agents do not provide cardiovascular benefit to patients with type 2 diabetes mellitus(T2 DM) and may even increase the risk of all-cause mortality. Based on research evidence published to date, these studies show that overload of energy could increase the incidence and prevalence of T2 DM, and reduction in the heat load can significantly reduce the incidence of T2 DM. Therefore, the essence of T2 DM is heat overload, meaning heat overload is the etiology of obese T2 DM. At the same time, results of numerous studies show that heat overloading is the cause of IR. IR and islet dysfunction are protective factors in intervening with heat overload.These drugs, which are based on the mechanisms of IR and islet insufficiency, increase caloric reserve and cause or worsen obesity, which is equivalent to exacerbating the basic etiology and the cardiovascular risk factor of T2 DM. Thus, a reasonable strategy for prevention and treatment of obese T2 DM appears to promote the negative balance of calories and the elimination of caloric reserves. Chinese herbal medicines can promote negative balance of heat in many aspects, which can bring new hope for prevention and treatment of T2 DM.
引用
收藏
页码:62 / 71
页数:10
相关论文
共 50 条
  • [31] Insulin Therapy in Type 2 Diabetes Mellitus
    Leahy, Jack L.
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2012, 41 (01) : 119 - +
  • [32] Insulin Therapy for Type 2 Diabetes Mellitus
    Wallia, Amisha
    Molitch, Mark E.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 311 (22): : 2315 - 2325
  • [33] Intracellular magnesium of obese and type 2 diabetes mellitus children
    Takaya J.
    Yamato F.
    Kuroyanagi Y.
    Higashino H.
    Kaneko K.
    Diabetes Therapy, 2010, 1 (1) : 25 - 31
  • [34] Effect of ketotifen in obese patients with type 2 diabetes mellitus
    El-Haggar, Sahar M.
    Farrag, Wael F.
    Kotkata, Fedaa A.
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2015, 29 (03) : 427 - 432
  • [35] Incretin Therapy for Type 2 Diabetes Mellitus
    Klonoff, David C.
    ADVANCES IN THERAPY, 2010, 27 (12) : 881 - 894
  • [36] BONE MARKERS AND PERIPHERAL SEROTONIN IN MENOPAUSAL WOMEN WITH AND WITHOUT TYPE 2 DIABETES MELLITUS: HOW FAR?
    Carsote, M.
    Capatina, C.
    Geleriu, A.
    Mihai, A.
    Manda, D.
    Caragheorgheopol, A.
    Stefanescu, A. M.
    Poiana, C.
    OSTEOPOROSIS INTERNATIONAL, 2015, 26 : S355 - S355
  • [37] Pharmacologic therapy for type 2 diabetes mellitus
    DeFronzo, RA
    ANNALS OF INTERNAL MEDICINE, 2000, 133 (01) : 73 - 74
  • [38] Incretin therapy for type 2 diabetes mellitus
    David C. Klonoff
    Advances in Therapy, 2010, 27 : 881 - 894
  • [39] Pharmaceutical therapy of diabetes mellitus type 2
    Laubner, K.
    Seufert, J.
    INTERNIST, 2007, 48 (03): : 297 - 308
  • [40] Multifactorial intervention in patients with type 2 diabetes - how much can be gained and how low should we go?
    Gaede, Peter
    ENDOCRINE JOURNAL, 2010, 57 : S218 - S218